Zhitong Financial App News, Federal Pharmaceuticals (03933.HK) announced that the new drug clinical trial registration application (IND) for UBT48128 tablets, a Class 1 innovative drug independently developed by Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, for overweight or obesity and type 2 diabetes, was approved by the US Food and Drug Administration (FDA). The IND numbers are 182060 and 182061, respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.